Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women

Background: We describe the incidence and duration of cervical human papillomavirus (HPV) infection episodes along with the risk of infection reappearance following a period of nondetection. Methods:Women (1,788) ages 16 to 23 years underwent cytologic testing and PCR-based testing of cervical swab samples for HPV DNA (HPV-16/18/31/33/35/45/52/58/59) at ?6-month intervals for up to 4 years in the context of a phase 3 clinical trial (placebo arm). HPV type - specific incidence rates were estimated per 100 person-years. Duration of type-specific cervical infection episodes and risk of reappearance following a period of nondetection were estimated using Kaplan-Meier methods. Results: HPV-16 exhibited the highest (5.9), and HPV-35 and HPV-33 exhibited the lowest (1.0) incidence rates per 100 person-years. Mean cervical infection durations ranged from 13 months for HPV-59 to 20 months for HPV-16 and 58 (with ongoing infections censored at the time of treatment, if done). The risk of cervical infection reappearance within ?3 years following a period of nondetection ranged from 0% to 16% across HPV types, with a mean of 8%. Limited evidence was found for a role of false-positive HPV tests, missed infections that were above the threshold for detection, or new acquisition of infection in accounting for patterns of infection reappearance. Conclusions: Incidence of high-risk cervical infection was observed to vary considerably more across HPV types than infection duration. A nontrivial proportion of women exhibited infection reappearance following a period of nondetection, with a potential explanation for many such events observed within this analysis being a return to detectable levels of a previously acquired infection. Impact: The risk of HPV infection reappearance following a period of nondetection has not been previously reported for individual HPV types, and this study finds that a nontrivial proportion of infected women exhibit reappearances. Future studies could ascertain subject-level factors that potentially modify the risk of infection reappearance. ©2010 AACR.

• Fecha de publicación: 2010
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/23631
• Acceso en línea: https://doi.org/10.1158/1055-9965.EPI-09-1235; https://repository.urosario.edu.co/handle/10336/23631
• Palabra clave: Adolescent; Adult; Article; Clinical feature; Clinical trial; Controlled study; Cytology; Disease classification; Disease duration; Female; Human; Human tissue; Incidence; Major clinical study; Papillomavirus infection; Polymerase chain reaction; Priority journal; Uterine cervix; Double blind procedure; Genetics; Isolation and purification; Papilloma virus; Papillomavirus infections; Phase 3 clinical trial (topic); Prevalence; Randomized controlled trial (topic); Uterine cervical diseases; Virology; Young adult; Virus dna; Adolescent; Double-blind method; Female; Humans; Incidence; Papillomaviridae; Papillomavirus infections; Polymerase chain reaction; Prevalence; Randomized controlled trials as topic; Uterine cervical diseases; Young adult; phase iii as topic; viral; Clinical trials; Dna
• License: Abierto (Texto Completo)